Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA ...

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top ...